Inspira Technologies Launches Global Rollout of ART100 System

Inspira Technologies Oxy BHN ( (IINN) ) just unveiled an announcement.

On May 29, 2025, Inspira Technologies announced the global commercial rollout of its FDA-cleared ART100 system, following successful clinical implementations in the U.S. The company is actively engaged in sales discussions with governmental and private organizations, with deliveries expected in the second half of 2025. This strategic shift aims to enhance shareholder value and aligns with the growing demand for scalable respiratory solutions, potentially positioning Inspira as a key player in public health initiatives and cross-sector partnerships.

Spark’s Take on IINN Stock

According to Spark, TipRanks’ AI Analyst, IINN is a Underperform.

The overall stock score reflects significant financial instability, as indicated by ongoing losses and reliance on external funding. The technical analysis shows bearish sentiment, with the stock under pressure. Valuation is challenging due to negative earnings and lack of dividend yield, making the stock less appealing to investors.

To see Spark’s full report on IINN stock, click here.

More about Inspira Technologies Oxy BHN

Inspira Technologies is a commercial-stage medical device company specializing in advanced respiratory support and real-time blood monitoring solutions. The company’s FDA-cleared INSPIRA ART100 system is approved for cardiopulmonary bypass in the U.S. and ECMO procedures outside the U.S. Inspira is also developing the INSPIRA ART500 and the HYLA blood sensor, positioning itself as a strategic platform within the critical care and MedTech landscape.

Average Trading Volume: 315,059

Technical Sentiment Signal: Sell

Current Market Cap: $11.31M

For a thorough assessment of IINN stock, go to TipRanks’ Stock Analysis page.